DMK Pharmaceuticals Corporation

DMKPQ

US00547W3079

Pharmaceuticals

Delayed OTC Markets Other stock markets 09:30:03 2024-07-09 am EDT			5-day change	1st Jan Change
0.03 ^USD	-25.00%		+2.39%	-95.72%

Jul. 01	Ebrahim ?Eboo? Versi Separates from His Role as Chief Executive Officer of DMK Pharmaceuticals Corporation	CI
Jul. 01	DMK Pharmaceuticals Corporation Announces Management Changes	CI

Ebrahim ?Eboo? Versi Separates from His Role as Chief Executive Officer of DMK Pharmaceuticals Corporation

July 01, 2024 at 06:04 am EDT

DMK Pharmaceuticals Corporation announced that effective June 27, 2024, Mr. Ebrahim ?Eboo? Versi, M.D., Ph.D. was separated from his role as Chief Executive Officer of the Company.

Latest news about DMK Pharmaceuticals Corporation

Ebrahim ?Eboo? Versi Separates from His Role as Chief Executive Officer of DMK Pharmaceuticals Corporation	Jul. 01	CI
DMK Pharmaceuticals Corporation Announces Management Changes	Jul. 01	CI
ZMI Pharma, Inc acquired Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation for $3.2 million.	Jun. 19	CI
First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation	Jun. 14	CI
Motion for Case Conversion Filed by DMK Pharmaceuticals Corporation	Jun. 11	CI
First Motion for Exclusivity Period Extension Filed by DMK Pharmaceuticals Corporation	May. 30	CI
Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation	May. 08	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Bidding Procedure Approved for DMK Pharmaceuticals Corporation	Apr. 04	CI
Motion for Asset Sale Filed by DMK Pharmaceuticals Corporation	Mar. 21	CI
DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index	Feb. 07	CI
Motion for Joint Administration Approved for DMK Pharmaceuticals Corporation	Feb. 06	CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index	Feb. 05	CI
Motion for Joint Administration Filed by DMK Pharmaceuticals Corporation	Feb. 02	CI
DMK Pharmaceuticals Corporation Filed for Bankruptcy	Feb. 02	CI
DMK Pharmaceuticals Corporation Announces Board Appointments	Jan. 31	CI
Maxim Starts DMK Pharmaceuticals With Buy Rating, $1.50 Price Target	Dec. 07	MT
DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI	Nov. 28	CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) added to NASDAQ Composite Index	Nov. 20	CI
Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index	Nov. 20	CI
Earnings Flash (DMK) DMK PHARMACEUTICALS CORPORATION Reports Q3 Revenue $9,062	Nov. 14	MT
DMK Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
DMK Pharmaceuticals Corporation Announces CFO Changes	23-10-19	CI
DMK Pharmaceuticals Corporation Announces Executive Changes	23-10-19	CI

Chart DMK Pharmaceuticals Corporation

Duration

Period

More charts

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Companyâs commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Companyâs lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Companyâs other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinsonâs disease.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
DMK PHARMACEUTICALS CORPORATION	-95.72%	404K
ELI LILLY AND COMPANY	+59.18%	827B
NOVO NORDISK A/S	+38.38%	634B
JOHNSON & JOHNSON	-6.54%	350B
MERCK & CO., INC.	+15.09%	319B
ABBVIE INC.	+8.43%	294B
ASTRAZENECA PLC	+12.68%	240B
NOVARTIS AG	+14.40%	221B
ROCHE HOLDING AG	+0.04%	219B
AMGEN INC.	+8.85%	167B

Other Pharmaceuticals

DMK Pharmaceuticals Corporation

Equities

DMKPQ

US00547W3079

Pharmaceuticals

Ebrahim ?Eboo? Versi Separates from His Role as Chief Executive Officer of DMK Pharmaceuticals Corporation

Latest news about DMK Pharmaceuticals Corporation

Chart DMK Pharmaceuticals Corporation

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals